Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

View Full Paper

Ask AI

Bookmark

Erdafitinib shows targeted therapeutic activity in refractory solid tumors harboring fibroblast growth factor receptor alterations, meeting protocol response criteria.
The phase ii study within the national NCI-MATCH trial evaluated oral erdafitinib across multiple advanced solid tumor types with verified FGFR amplifications.
Findings highlight the clinical utility of targeting fibroblast growth factor receptor amplifications, supporting precision oncology strategies for refractory cancers.

No abstract yet

We only have this paper's title and publication details.

No takes yet. Share an insight, caveat, or question.

Phase II trial demonstrates erdafitinib activity in advanced tumors with FGFR amplifications, highlighting targeted therapeutic potential.

Gong et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Phase II trial demonstrates erdafitinib activity in advanced tumors with FGFR amplifications, highlighting targeted therapeutic potential.